At what enterprise value was BIOFARMA GROUP acquired in 2022?

During the acquisition of BIOFARMA GROUP by ARDIAN in 2022, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of BIOFARMA GROUP when it was acquired by ARDIAN?

The estimated EV/EBITDA multiple for BIOFARMA GROUP is in the range of Above 20x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was BIOFARMA GROUP acquired by ARDIAN?

BIOFARMA GROUP was acquired by ARDIAN in 2022.

What was the revenue of BIOFARMA GROUP at the time of the deal?

The revenue of BIOFARMA GROUP at the time of the deal is estimated to be in the range of 250M - 500M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of BIOFARMA GROUP during the acquisition?

BIOFARMA GROUP's EBITDA is estimated to be in the range of 50M - 100M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the BIOFARMA GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the BIOFARMA GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/communiques-de-presse/ardian-acquiert-une-participation-majoritaire-dans-biofarma-group-leader

← DATABASE

Home Database Healthcare & PharmaBIOFARMA GROUP

01/2022

BIOFARMA GROUP acquired by ARDIAN

ITALY Life Sciences / Pharma & Biotech / CDMO EV 1b - 4b EUR

Context

Ardian acquired a majority stake in Biofarma Group from White Bridge Investments. Ardian's entry is designed to transform the European leader into a global champion, specifically targeting expansion into the US and APAC markets while maintaining its technological lead in the high-margin probiotic segment.

BIOFARMA GROUP, which reported an EBITDA margin of in 2022, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Biofarma Group is a leading European Contract Development and Manufacturing Organization (CDMO) for the nutraceutical and personal care industries. It specializes in the development, production, and packaging of food supplements, medical devices, probiotics, and cosmetics. The group is recognized for its high R&D capabilities and state-of-the-art production facilities.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2022	FRESENIUS	MABXIENCE	SPAIN	CDMO
02/2022	MONTAGU PRIVATE EQUITY / PARTNERS GROUP	HTL BIOTECHNOLOGY	FRANCE	CDMO
01/2022	ANJAC BEAUTY & HEALTH	APOLLO HEALTHCARE CORP.	CANADA	CDMO
01/2022	PERMIRA	KEDRION	ITALY	CDMO
01/2022	PERMIRA	BIO PRODUCTS LABORATORY (BPL)	UNITED KINGDOM	CDMO
12/2021	INTEGER	OSCOR	UNITED STATES	Implants & Prosthetics
12/2021	THE CARLYLE GROUP / GTCR	RESONETICS	UNITED STATES	Medical Devices
12/2021	WINNCARE	PHARMAOUEST INDUSTRIES	FRANCE	Medical Devices
12/2021	PLANMECA GROUP	KAVO DENTAL	GERMANY	Medical Devices
11/2021	COLOPLAST	ATOS MEDICAL	SWEDEN	Medical Consumables

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 250M - 500M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of BIOFARMA GROUP by ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: ardian